GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT basliginda one cikan gelisme: The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.